H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Interpace Diagnostics Group Inc (NASDAQ: IDXG) today and set a price target of $3. The company’s shares closed yesterday at $1.60.
Selvaraju wrote:
“Our price target is derived from a market value of the firm at $115M, which includes a discounted cash flow analysis based asset value for the company’s three commercialized laboratory-developed tests (LDTs), with a 15% discount rate and a 2% terminal growth rate. Risks include: (1) failure of the company’s LDTs to secure reimbursement; (2) failure of the company’s LDTs to achieve commercial success due to lower-than-expected market size and/or penetration rates, and/or greater competition; and (3) potential dilution risk.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 3.7% and a 39.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.
Interpace Diagnostics Group Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.50, implying an 118.8% upside from current levels. In a report issued on September 24, Maxim Group also maintained a Buy rating on the stock with a $4 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.80 and a one-year low of $0.77. Currently, Interpace Diagnostics Group Inc has an average volume of 670.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Interpace Diagnostics Group, Inc. is an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
